Switch theme
Sign up to access all valuation multiples
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
2011
1.8K+
LTM Revenue $1.5B
LTM EBITDA $399M
$3.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alkermes has a last 12-month revenue of $1.5B and a last 12-month EBITDA of $399M.
In the most recent fiscal year, Alkermes achieved revenue of $1.6B and an EBITDA of $495M.
Alkermes expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alkermes valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.7B | $1.6B | XXX | XXX | XXX |
| Gross Profit | $894M | $1.4B | XXX | XXX | XXX |
| Gross Margin | 54% | 91% | XXX | XXX | XXX |
| EBITDA | $519M | $495M | XXX | XXX | XXX |
| EBITDA Margin | 31% | 32% | XXX | XXX | XXX |
| Net Profit | -$158M | $356M | XXX | XXX | XXX |
| Net Margin | -10% | 23% | XXX | XXX | XXX |
| Net Debt | $0.8M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alkermes's stock price is $28.
Alkermes has current market cap of $4.5B, and EV of $3.9B.
See Alkermes trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.9B | $4.5B | XXX | XXX | XXX | XXX | $2.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alkermes has market cap of $4.5B and EV of $3.9B.
Alkermes's trades at 2.6x LTM EV/Revenue multiple, and 9.7x LTM EBITDA.
Analysts estimate Alkermes's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alkermes and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.9B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 7.8x | XXX | XXX | XXX |
| P/E | 12.4x | XXX | XXX | XXX |
| P/E/Growth | -0.5x | XXX | XXX | XXX |
| EV/FCF | 9.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlkermes's NTM/LTM revenue growth is -7%
Alkermes's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Alkermes's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alkermes's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alkermes and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 57% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alkermes acquired XXX companies to date.
Last acquisition by Alkermes was XXXXXXXX, XXXXX XXXXX XXXXXX . Alkermes acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alkermes founded? | Alkermes was founded in 2011. |
| Where is Alkermes headquartered? | Alkermes is headquartered in United States of America. |
| How many employees does Alkermes have? | As of today, Alkermes has 1.8K+ employees. |
| Who is the CEO of Alkermes? | Alkermes's CEO is Mr. Richard F. Pops. |
| Is Alkermes publicy listed? | Yes, Alkermes is a public company listed on NAS. |
| What is the stock symbol of Alkermes? | Alkermes trades under ALKS ticker. |
| When did Alkermes go public? | Alkermes went public in 1991. |
| Who are competitors of Alkermes? | Similar companies to Alkermes include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alkermes? | Alkermes's current market cap is $4.5B |
| What is the current revenue of Alkermes? | Alkermes's last 12-month revenue is $1.5B. |
| What is the current EBITDA of Alkermes? | Alkermes's last 12-month EBITDA is $399M. |
| What is the current EV/Revenue multiple of Alkermes? | Current revenue multiple of Alkermes is 2.6x. |
| What is the current EV/EBITDA multiple of Alkermes? | Current EBITDA multiple of Alkermes is 9.7x. |
| What is the current revenue growth of Alkermes? | Alkermes revenue growth between 2023 and 2024 was -6%. |
| Is Alkermes profitable? | Yes, Alkermes is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
